Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited（RDY）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
rdy · 股价预测 · 12 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 12 位华尔街分析师
Buy
12 位分析师
共识
评级分布
12 个月目标价
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $13.31
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $13.20 | ↓ 0.88% |
1-day model range: $13.15–$13.24. Peak: $13.24 (-0.88%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $15 | +9.4% |
| 2028 | $15 | +16.1% |
| 2029 | $16 | +20.8% |
| 2030 | $17 | +23.9% |
| 2031 | — | +26.0% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RDY · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-06-05 | HSBC | Upgrade ↑ | Hold→Buy |
| 2024-11-06 | Barclays | Maintains | Overweight→Overweight |
| 2024-07-30 | Barclays | Maintains | Overweight→Overweight |
| 2024-05-08 | Barclays | Maintains | Overweight→Overweight |
| 2024-01-29 | Barclays | Maintains | Overweight→Overweight |
| 2023-06-01 | Barclays | Maintains | Overweight→Overweight |
| 2022-10-31 | Barclays | Maintains | Overweight→Overweight |
| 2022-10-25 | Barclays | Maintains | Overweight→Overweight |
| 2022-09-12 | Barclays | Maintains | Overweight→Overweight |
| 2022-07-25 | Barclays | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Dr. Reddy's Laboratories Limited (RDY) stock. Of the recent 33 rating actions, 8 were upgrades and 9 were downgrades. 12 analysts currently cover RDY.
分析师推荐趋势
RDY analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$321.2B
↓ 7.8% YoY
Revenue Next Year
$345.1B
↑ 7.4% YoY
EPS This Year
$67.47
EPS Next Year
$60.13
↓ 10.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast RDY EPS of $67.47 for the current fiscal year, based on estimates from 2 analysts. The RDY revenue forecast is $321.2B for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
RDY 股价预测由两类独立数据源支撑：来自 12 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。RDY 的共识目标价为 $0.00（+0.0% 上行空间），分析师共识为 Buy。
RDY 的短期预测（明日）为 $13.20（-0.88%）。 RDY 对 2027 年的股价预测均值为 $15。 RDY 对 2030 年的预测区间为 $16–$17。
Dr. Reddy's Laboratories Limited 在 NYSE 上市，代码 RDY。RDY 在 2027 年的整体展望偏积极，在覆盖分析师中约 50% 对应 Buy 共识。
常见问题
RDY 预测 · 8 个问题根据 12 位华尔街分析师，RDY 的 12 个月平均目标价为 $0.00，最高 $0.00、最低 $0.00。若有图表，中位目标价可在上方查看。相对当前价 $13.31，隐含约 +0.0% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.